Clinical Trial Update: Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of UK-369,003 for lower urinary tract symptoms due to prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Lower Urinary Tract Symptoms

Drugs mentioned

• UK-369,003 (UK-369,003)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Hyperplasia | Phase 2 | Status: COMPLETED